Connect with us

Technology

Biobanking Market size is set to grow by USD 1.66 billion from 2024-2028, Growing demand for personalized medicine boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global biobanking market size is estimated to grow by USD 1.66 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.04% during the forecast period. Growing demand for personalized medicine is driving market growth, with a trend towards emergence of stem cells storage in biobanks. However, increasing ethical issues poses a challenge. Key market players include AMS Biotechnology Europe Ltd., ASKION GmbH, Azenta Inc., Bay Biosciences LLC, BioIVT LLC, Boca Biolistics LLC, CTIBiotech, Cureline Inc., Danaher Corp., Firalis SA, GENETICIST Inc., Greiner Bio One International GmbH, Hamilton Co., OraSure Technologies Inc., PHC Holdings Corp., Promega Corp., ProteoGenex Inc., Shanghai Genext Medical Technology Co. Ltd., Thermo Fisher Scientific Inc., and US Biolab Corp. Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Biobanking Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.04%

Market growth 2024-2028

USD 1669.1 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.36

Regional analysis

Europe, North America, Asia, and Rest of World (ROW)

Performing market contribution

Europe at 38%

Key countries

US, Germany, Japan, UK, and China

Key companies profiled

AMS Biotechnology Europe Ltd., ASKION GmbH, Azenta Inc., Bay Biosciences LLC, BioIVT LLC, Boca Biolistics LLC, CTIBiotech, Cureline Inc., Danaher Corp., Firalis SA, GENETICIST Inc., Greiner Bio One International GmbH, Hamilton Co., OraSure Technologies Inc., PHC Holdings Corp., Promega Corp., ProteoGenex Inc., Shanghai Genext Medical Technology Co. Ltd., Thermo Fisher Scientific Inc., and US Biolab Corp. Inc.

Market Driver

The biobanking market is experiencing significant growth due to the increasing demand for stem cell storage. Stem cells have the potential to address various medical needs in sectors like cardiology and oncology. New biobanking facilities, such as those launched by the Global Stem Cells Group in Chile, are dedicated to stem cell research to improve access to novel therapeutic resources. Research organizations are also investing in advanced production units to enhance supply chain efficiency and increase production capacities. Technological advancements, like IT in logistics and temperature-controlled solutions, minimize errors and enable large-scale stem cell therapy product manufacturing in a sterile environment. These investments present substantial growth opportunities for the biobanking market. 

The Biobanking Market is witnessing significant growth due to the increasing demand for human samples, particularly in the areas of blood, plasma, serum, urine, tissues, and cells. Disease-oriented biobanks and population-based biobanks are major segments, with cancer, respiratory diseases, and Alzheimer’s disease being key focus areas. Sustainability and financial support from public organizations are crucial for the industry’s growth. Tissue banks, blood banks, and stem cell biobanks are key players. Biobanking plays a vital role in drug development, and the life science segment is a significant consumer. Ethical challenges, regulatory scrutiny, and informed consent are crucial considerations. Technidata Medical Software and academic institutions are important partners. Emerging countries offer opportunities, but cold chain logistics and lab processing require attention. Biobanking technologies are advancing, enabling precision/personalized medicine, genetic testing, and regenerative medicines. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

Biobanking, the process of collecting, storing, and managing biological samples for research and diagnostic purposes, faces ethical concerns regarding privacy and consent. Informed consent is crucial to protect individuals’ identities. However, there are debates over the use of biobank data by private companies for their interests. Ethical issues surround the research on biological samples, particularly human embryonic stem cells, including cloning, embryo destruction, and safety concerns. These debates and disagreements may hinder the growth of the global biobanking market, as they impact research and decision-making in various countries.The biobanking market presents both challenges and opportunities for smaller companies with limited financial resources. One major barrier to entry is the high investment required for infrastructure, including automated storage systems and tissue processing facilities. Ongoing maintenance, operational costs, software updates, and repairs add to the financial burden. Training of skilled resources is also essential for effective collection, storage management, sample distribution, and administration. Developed markets offer lucrative opportunities, but high operational costs can be a challenge. New technologies and availability of biospecimens for research present opportunities, but availability and effective collection come with their own set of challenges. The long-term economic situation requires careful consideration of costs associated with in-case collection, tissue processing, and storage management. Low-cost manufacturing advantage can help smaller companies compete, but they must stay updated with the latest technologies to remain competitive.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This biobanking market report extensively covers market segmentation by

Type 1.1 Physical1.2 VirtualProduct 2.1 Equipment2.2 ConsumablesGeography 3.1 Europe3.2 North America3.3 Asia3.4 Rest of World (ROW)

1.1 Physical- The Biobanking Market is a significant industry that focuses on collecting, storing, and managing biological samples for research and diagnostic purposes. Companies in this market provide services such as sample collection, processing, and long-term storage. Key players include Thermo Fisher Scientific, Qiagen, and Corning Incorporated. Market growth is driven by increasing research and development activities in the healthcare sector and advancements in biotechnology. Biobanks play a crucial role in enabling personalized medicine and drug discovery.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The biobanking market encompasses the collection, processing, storage, and distribution of human samples, including blood, plasma, serum, urine, tissues, and cells, for research and diagnostic purposes. Two main types of biobanks exist: disease-oriented and population-based. Disease-oriented biobanks focus on specific diseases, such as cancer, respiratory diseases, and Alzheimer’s disease, while population-based biobanks collect samples from large and diverse populations. Tissue banks and blood banks are specialized types of biobanks. Biobanking plays a crucial role in drug development, particularly in the fields of regenerative medicines, cancer, and personalized medicine. Sustainability, financial support from public organizations, and ethical challenges, including informed consent and sample storage, are key considerations. Technidata Medical Software and academic institutions also contribute to the biobanking landscape. Stem cell biobanks are a significant segment of the market, with potential applications in regenerative medicine. Ethical challenges, such as ensuring informed consent and maintaining sample integrity, must be addressed to ensure the success and legitimacy of biobanking initiatives.

Market Research Overview

The Biobanking Market encompasses the collection, processing, storage, and distribution of human biological samples, including blood, plasma, serum, urine, tissues, and cells. Biobanks come in various forms such as disease-oriented, population-based, tissue, blood, and stem cell biobanks. The market caters to diverse applications like drug development, cancer, respiratory diseases, Alzheimer’s disease, and regenerative medicines. Sustainability and financial support from public organizations are crucial. Technidata Medical Software and other biobanking technologies facilitate efficient operations. Ethical challenges and emerging countries pose barriers to entry for smaller biobanking companies with limited financial resources. Informed consent, sample storage, and lab processing are key considerations. The Blood segment and Cells & Tissue segment dominate the Life Science segment. Precision/personalized medicine, genetic testing, biomedical research, and genetic studies are significant applications. The Biobanking Industry faces regulatory scrutiny and high operational costs, but also offers lucrative opportunities due to new technologies and low-cost manufacturing advantages. Ongoing maintenance, software updates, repairs, and training are essential for biobanking operations. The funding scenario is dynamic, with investments and funding influencing buying behavior. Newborn biobanks and automated equipment contribute to efficiency and quality. Biobanking operations require skilled resources and adherence to regulatory guidelines. Biospecimens are vital for research, and new technologies aim to improve availability.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

TypePhysicalVirtualProductEquipmentConsumablesGeographyEuropeNorth AmericaAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/biobanking-market-size-is-set-to-grow-by-usd-1-66-billion-from-2024-2028–growing-demand-for-personalized-medicine-boost-the-market-technavio-302210033.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Desay SV Reshapes the New Ecosystem of Smart Mobility

Published

on

By

SHANGHAI, April 27, 2025 /PRNewswire/ — On April 22, Desay SV unveiled 2030 development strategy, new mission and vision under the theme “Unlimited Intelligence”. The company simultaneously showcased Smart Solution 3.0, an AI-driven smart mobility solution designed for future transportation.

To be A New Paradigm

Following driver-assistance technologies are becoming increasingly widespread, high level driver-assistant from optional to must be for the industry. However, the industry still faces significant hurdles, including complex development processes, suboptimal user experience, weak value perception, and challenges in development turning into mass production.

Gao Dapeng emphasized that only a new paradigm can cross the industry’s chasm. Over the past five years, Desay SV has achieved a 34% CAGR in R&D investment, established 12 global R&D centers, and built a 4,200-strong engineering team. Desay SV has undergone a remarkable transformation from a technology reserve to a scaled application and a leader in the industry. This journey has been characterized by a relentless reinvention of outdated frameworks, systems, and models. 

In discussing future challenges, Gao Dapeng, Chairman of Desay SV, outlined Desay SV core value proposition: open for collaboration, insist on full-stack capability, and rapid implementation. Guided by the mission of “Creating Safe, Delightful and Sustainable Mobility” and the vision of “Smarter Mobility for All,” the company will expand technological capabilities, broaden ecosystem partnerships, and shape next-gen mobility solutions.

Enhancing the Full-Stack Capability for Continuous Advancement

Currently, 1 out of every 3 vehicles in China is equipped with Desay SV products and solutions – the market penetration driven by the company’s R&D innovation and ecosystem-building capabilities. With nearly four decades of technological dedication, Desay SV insists on shaping the underlying architecture with innovative synergies and achieving full-stack expertise in both hardware and software.

Addressing challenges including ill-defined user demands, complex industry collaboration, and escalating innovation costs in the AI era, Desay SV CEO Xu Jian presented a three-year solution termed “One Architecture + Three Businesses + Three Commitments”. The “One Architecture” is the integrated architecture covering the vehicle, road, and cloud; the “Three Businesses” represent the technological upgrades of the intelligent cabin, intelligent driving, and connected service. The “Three Commitments” encompass sustained investment in all-domain capability, multi-modal integration across value chains for ecosystem advancement, collaboration across R&D-to-manufacturing value chains to strengthen the industrial ecosystem and human-centric commitments to deliver all-encompassing intelligent mobility ecosystems.

Xu Jian emphasized that the AI variable will accelerate intelligent vehicle adoption. Desay SV maintains a triple-phase development cadence – mass production, pre-research, and technology reserves – to continuously roll out innovative products and technology solutions tailored to future mobility demands. While executing these foundational solutions, we’re exploring optimized and potential pathways for the future.

Crafting the Mobile Embodied Agent–Smart Solution 3.0

The release of “Desay SV Mobility Trends Analysis Report in the AI Era” provided cutting-edge insights. The report conducts an in-depth analysis of user profiles in the AI era, proposing six trends. The debut of Smart Solution 3.0 represents the systematic implementation of these AI mobility future trends.

Driven by AI advancements, Smart Solution 3.0 integrates over 150 cutting-edge technologies spanning spatial computing, neural augmentation, and ambient stealth intelligence. Through four innovative scenarios—Verdant Forest, Hyper Sense Activation, Sentinel Care and Comfort Mode—the system displays a human-vehicle-environment ecosystem characterized by multi-sensory interaction, deep emotional resonance, real-time biometric tracking, and context-aware risk prediction. This technological convergence promotes the accelerated evolution of intelligent vehicles into Mobile Embodied Agents.

In the AI-empowered mobility era, Desay SV will harness engineering prowess, cost-optimized solutions, and open ecosystem architecture to forge safe, delightful, and sustainable mobility experiences, advancing the vision of “Smarter Mobility for All” to catalyze the golden age of assisted driving systems.

About Desay SV

Desay SV (002920.SZ) is a leading mobility technology company with R&D and service branches in Germany, Japan, Singapore, Spain, USA, etc. The company focuses on efficiently integrating smart cabin, smart drive, and smart service. Relying on 39 years of accumulation, Desay SV has excelled in R&D, design, quality management, and intelligent manufacturing. Desay SV’s continuous innovation and comprehensive capabilities earn the long-term trust of global customers, including Chery, Geely, SAIC, Toyota, Volkswagen, Volvo, etc., and have helped it rank 74th in the Automotive News 2024 top 100 global auto parts suppliers. For more information, please visit Desay SV online at www.desaysv.com or follow us on: https://www.linkedin.com/company/13690363

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/desay-sv-reshapes-the-new-ecosystem-of-smart-mobility-302439051.html

SOURCE Desay SV

Continue Reading

Technology

When a British Influencer Meets the Canton Fair

Published

on

By

GUANGZHOU, China, April 26, 2025 /PRNewswire/ — “It looks like we are walking straight into the future.” said British influencer Jason talking to the camera at China Import and Export Fair, also widely known as the Canton Fair.

 

As the world’s largest trade exhibition, the 137th Canton Fair has attracted buyers from over 200 countries and regions, with over 30,000 companies participating in. All types of cutting-edge technologies created dazzling sparks in the lens of Jason at the Service Robots Zone.

In the smart home appliances section, Jason was drawn to a refrigerator that can “think”—it provides recipes based on ingredient inventory and even enables users to check its contents remotely via smartphone. In the new energy vehicle section, autonomous electric cars and swappable-battery scooters left Jason exclaiming, “This is the future of transportation!”

The significance of the Canton Fair goes far beyond an exhibition; it provides a stage for real-time global trade transactions. Every year, buyers from over 200 countries strike deals worth billions of dollars here, forging partnerships that shape global supply chains. “This is no ordinary trade show,” Jason said in his video. “As a global commerce hub, it showcases not just business opportunities but also the immense momentum behind ‘Made in China.'”

Jason’s video has attracted enthusiastic responses on international social media platforms, with many global netizens commenting, “Jason is the most enthusiastic explorer in China to share values of truth.” 

Want to experience the Canton Fair through Jason’s first-person perspective? Click on the video and join us on this journey of technology and commerce!

YouTube Link:https://www.youtube.com/watch?v=TvKvlB5qPOg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/when-a-british-influencer-meets-the-canton-fair-302439038.html

SOURCE The 137th Canton Fair

Continue Reading

Technology

ChangAn Outlines 2030 Vision at “Vast Ocean Plan: United Towards the Peak”-Themed Overseas Partner Conference in Chongqing

Published

on

By

The Company is rapidly accelerating its global expansion with the goal of becoming a world-class automobile brand.

CHONGQING, China, April 26, 2025 /PRNewswire/ — ChangAn Automobile (“ChangAn” or “the Company”), an intelligent low-carbon mobility technology company, recently hosted the 2025 Overseas Partner Conference in Chongqing under the theme “Vast Ocean Plan: United Towards The Peak.” The event brought together more than 500 partners from over 70 countries discuss the Company’s global achievements and share its future roadmap. During the conference, ChangAn unveiled its “2030 Vision,” pledging over $10 billion in global investment. The Company aims to reach 5 million in global vehicle sales by 2030. ChangAn also set its sights on becoming one of the world’s top 10 automobile brands.

ChangAn’s global business strategy continues to advance with an expected 5 million vehicles worldwide and 1.2 million overseas by 2030

In his keynote at the 2025 conference, Zhu Huarong, Chairman of ChangAn Automobile, highlighted the Company’s progress over five years in new energy, intelligence, and global business. Global sales rose 34.2% to 2.684 million vehicles in 2024, with 735,000 new energy vehicles and 536,000 sold internationally. “From product exports to brand globalisation, we are strengthening global competitiveness with the dual drive of ‘long-termism plus localized operations,'” Mr. Zhu said. Over the next five years, ChangAn will target five key overseas markets and expand localised production, branding, and customer service.

ChangAn’s overseas sales ranked among the top 3 in China’s automobile exports in 2024

At the conference, Li Mingcai, Executive Vice President of ChangAn Automobile, highlighted key global milestones. The Company launched its first international NEV manufacturing base in Thailand and developed eight overseas production partnerships, reaching a capacity of 580,000 units. In 2024, ChangAn ranked among China’s top three auto exporters, with over 500,000 vehicles sold internationally and revenue surpassing $11 billion. The brand expanded into 20 new countries, entering over 100 globally, and now operates 1,150 sales channels. CHANG-AN, DEEPAL, and AVATR gained international recognition, with ChangAn joining the “BrandZ Top 50 Chinese Global Brands” just 14 months after launching the Vast Ocean Plan. “In the wave of anti-globalization, ChangAn Automobile has confirmed the strength of China’s smart manufacturing with nine consecutive years of export growth,” Mr. Li said.

The 2025 “dual-track” development plan will see 20 new cars launched internationally

Technological innovation remains at the core of ChangAn’s global strategy, said Executive Vice President Wang Xiaofei. The Company has invested over 114.8 billion yuan in R&D and established an international team of 18,000, including 5,000 software and AI specialists. Its 2025 plan includes a dual-track fuel and new energy strategy. Fossil-fuel vehicles will target markets in Central and South America, the Middle East and Africa, and Eurasia, while new energy vehicles will focus on Asia Pacific and Europe. ChangAn is building a unified global brand structure through CHANG-AN, DEEPAL, and AVATR, executing a “1+N” brand strategy — one global IP and multiple localised campaigns annually. Product-wise, 20 new global models (10 fuel, 10 NEVs) will be launched, including the CS75PLUS, DEEPAL S05, AVATR 07, and CHANG-AN Q07.

ChangAn remains confident and committed to future growth. Moving forward, the Company will focus on building a “competitiveness plus high quality” strategy, leveraging its core strengths and technology innovation to expand its footprint globally and further elevate its international influence.

View original content to download multimedia:https://www.prnewswire.com/news-releases/changan-outlines-2030-vision-at-vast-ocean-plan-united-towards-the-peak-themed-overseas-partner-conference-in-chongqing-302439041.html

SOURCE ChangAn Automobile

Continue Reading

Trending